← Leaderboards
Ben J Samelson-Jones
Children'S Hosp Of Philadelphia
$4,366,849
Attributed
$4,783,099
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,783,099 · 4
By mechanism
R01$3,038,402 · 2
P01$1,107,065 · 1
K08$637,632 · 1
Top collaborators
- Michael C. Milone2 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Sriram Krishnaswamy$22,716,630
- Bruce Alan Sullenger$24,141,070
- Rodney M Camire$12,955,560
- Michael C. Milone$6,962,068
- Lindsey Allison George$1,334,602
Others in their field
Other Emerging Leaders on “Hemophilia A”
- Timothy Nichols · Univ Of North Carolina Chapel Hill$5,542,798
- Grier P Page · Research Triangle Institute$3,205,882
- Allison May Keeler-Klunk · Univ Of Massachusetts Med Sch Worcester$2,714,081
- Hyungseok Jang · University Of California, San Diego$2,412,293
- Jesse Bruce Owens · University Of Hawaii At Manoa$2,313,515
- Glaivy Batsuli · Emory University$2,194,835
Research focus
Hemophilia AProteinsBlood Coagulation DisordersSafetySuccessCellsLinkHemorrhageGene TherapyImmune ResponseFactor ViiiNovel TherapeuticsF8 GeneBindingHemostatic FunctionIn VivoMouse ModelMutationCostDoseBaseAdeno-Associated Viral VectorBlood Coagulation FactorB-Lymphocytes
Grant awards (11)
Translating Mechanistic Insights into Intrinsic Xase Function$501,865
P01 · FY2025 · HL · contact PI
Immune tolerance induction by AAV-FVIII gene therapy for canine hemophilia A with inhibitors$723,852
R01 · FY2024 · HL · contact PI
Translating Mechanistic Insights into Intrinsic Xase Function$605,200
P01 · FY2024 · HL · contact PI
Immune tolerance induction by AAV-FVIII gene therapy for canine hemophilia A with inhibitors$738,625
R01 · FY2023 · HL · contact PI
Immune tolerance induction by AAV-FVIII gene therapy for canine hemophilia A with inhibitors$743,425
R01 · FY2022 · HL · contact PI
Rational Development of Bioengineered Factor IX Variants for Hemophilia B Therapy$159,408
K08 · FY2021 · HL · contact PI
Engineering cellular immunotherapy to modulate immune responses in hemophilia$416,250
R01 · FY2020 · HL · contact PI
Rational Development of Bioengineered Factor IX Variants for Hemophilia B Therapy$159,408
K08 · FY2020 · HL · contact PI
Engineering cellular immunotherapy to modulate immune responses in hemophilia$416,250
R01 · FY2019 · HL · contact PI
Rational Development of Bioengineered Factor IX Variants for Hemophilia B Therapy$159,408
K08 · FY2019 · HL · contact PI
Rational Development of Bioengineered Factor IX Variants for Hemophilia B Therapy$159,408
K08 · FY2018 · HL · contact PI